BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis ...Middle East

Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across measures of peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis – indicating sustained...

Hence then, the article about bimzelx bimekizumab bkzx three year rheumatology data at acr 2025 demonstrated sustained inflammation control in psoriatic arthritis and axial spondyloarthritis was published today ( Saturday 25/10/2025 - 06:12 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis )

Also on site :

• Crews respond to large fire at Denny Hamlin's parents' house in Stanley: Sources
• XPENG-Peking University Collaborative Research Accepted by AAAI 2026: Introducing a Novel Visual Token Pruning Framework for Autonomous Driving
• John Legend Celebrates 47th Birthday With Family Slime Outing in New York